ValiRx plc (LON:VAL – Get Free Report)’s stock price rose 24.8% on Tuesday . The stock traded as high as GBX 0.80 ($0.01) and last traded at GBX 0.78 ($0.01). Approximately 6,398,107 shares were traded during trading, an increase of 353% from the average daily volume of 1,411,171 shares. The stock had previously closed at GBX 0.63 ($0.01).
ValiRx Price Performance
The company has a market cap of £1.04 million, a price-to-earnings ratio of -39.25 and a beta of 0.59. The company has a fifty day moving average price of GBX 1.35 and a two-hundred day moving average price of GBX 1.92. The company has a current ratio of 6.65, a quick ratio of 1.27 and a debt-to-equity ratio of 0.49.
ValiRx Company Profile
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer.
Further Reading
- Five stocks we like better than ValiRx
- 3 Warren Buffett Stocks to Buy Now
- 3 Must-Hold Stocks with Double-Digit Upside for 2025
- The Most Important Warren Buffett Stock for Investors: His Own
- Micron: Why Now Is the Time to Be Brave
- Profitably Trade Stocks at 52-Week Highs
- 3 Stocks That Wall Street Insiders Can’t Stop Buying
Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with MarketBeat.com's FREE daily email newsletter.
